eligibility_summary
Adults (≥18) with relapsed/refractory, histologically confirmed large B‑cell lymphoma after last therapy, measurable disease, ECOG 0–1, adequate blood/renal/liver function, can stay within 1 hour of site for 4 weeks post‑infusion. Cohort 1: prior CD19 CAR‑T required. Cohort 3: ≥2 prior lines incl. a bispecific T‑cell engager. Excludes significant comorbid illness, active infection, or prior allogeneic transplant/cell therapy. Other criteria may apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05972720 tests firicabtagene autoleucel (firi-cel/CRG-022), an autologous, gene‑modified CAR T‑cell therapy targeting CD22 for relapsed/refractory large B‑cell lymphoma after CD19 CAR T. Mechanism: patient T cells are engineered to express a CD22‑specific CAR, CAR engagement activates T‑cell signaling (CD3ζ/costimulation), driving proliferation, cytokine release, and perforin/granzyme‑mediated killing of CD22+ malignant B cells, on‑target B‑cell aplasia may occur. Lymphodepleting conditioning: fludarabine (purine analog, DNA synthesis inhibitor causing lymphocyte depletion) and cyclophosphamide (alkylating agent, cytotoxic/immunosuppressive) to reduce host lymphocytes and enhance CAR T expansion. Targets: CD22 on LBCL cells (and normal B cells), effector cells are autologous T cells, pathways include CAR‑mediated T‑cell activation and cytotoxicity. Trial status: terminated by sponsor.